This program project will require the procurement and processing of a large bulk of histopathologic materials. These materials need to be processed, not only for routine histopathologic diagnosis of the tumor and premalignant lesions, but also for the various immunohistochemical and in situ hybridization studies proposed in the basic research projects. Preparation of tissue samples for these studies cannot be processed by a regular pathology laboratory since they require special care in their handling. For example, to obtain optimum results with mRNA in situ hybridization, all glassware should be baked, and tissue sections need to be handled with special care to avoid RNAase contamination. This Histology Laboratory Core will respond to such a special need and will prepare and distribute adequate tissue samples for the studies proposed in Projects 4 through 6. It will also function as a liaison with the Department of Pathology to coordinate the handling of pathology slides and paraffin blocks sent from collaborating institutions (e.g.,RTOG and CCOP institutions for Project 1). In addition, this core will process the immunohistochemical staining for the conduct of Project 3. Another major function of the laboratory will be the procurement and storage of both normal and malignant tumor samples for future use. This Core facility will become increasingly important since the proposed studies may find new molecular biologic of biochemical markers of interest that would warrant re-examination of some samples in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052051-10S1
Application #
6577743
Study Section
Project Start
2002-03-26
Project End
2002-11-30
Budget Start
Budget End
Support Year
10
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications